

Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome

Marie-Elisabeth Toubert¹, Elif Hindie¹, Lucia Rampin¹,
Adil Al-Nahas², Domenico Rubello³

¹Nuclear Medicine Department — PET Unit, Saint-Louis Hospital,
1 avenue Claude Vellefaux, 75010 Paris, France

²Department of Nuclear Medicine, Hammersmith Hospital, London,
United Kingdom

³Nuclear Medicine Service, PET Unit, "S. Maria della Misericordia",
Rovigo Hospital, Istituto Oncologico Veneto (IOV), Italy

[Received 23 VIII 2007; Accepted 15 XI 2007]

Abstract

The remarkably good prognosis and long-term survival in differentiated thyroid cancer (DTC) are significantly reduced in patients with distant metastasis (DM). Multi-site metastases are associated with a high mortality rate reaching 92% at 5 years necessitating early diagnosis and treatment. The most common site of metastases are the lungs, followed by the bone, with the former having better prognosis than the latter due to late detection. A number of factors contribute to the development of DM including large and multifocal primary tumour, extrathyroidal extension, aggressive histology and advanced age. In patients with good ¹³¹I uptake, ¹³¹I therapy appears highly effective and should be offered up to a cumulative activity of 22 GBq. Other measures such as surgery, radiotherapy, arterial embolisation and cementoplasty may be required.

If there is low or no ¹³¹I uptake, FDG-PET should be obtained due to its prognostic impact. It may help in selecting patients for other modalities such as cytotoxic chemotherapy and redifferentiation therapy by 13-*cis* retinoic acid. The development of tyrosine kinase inhibitors has raised hopes in providing alternative therapy for bone metastasis, especially in older age

groups with poorly differentiated tumours with no ¹³¹I uptake but good uptake of FDG.

Key words: metastases, differentiated thyroid cancer, diagnosis, treatment

Although differentiated thyroid cancer (DTC) is usually of good prognosis [1], patients with distant metastases (DM) (4–15%) [2–6] are known to have a markedly reduced survival rate of 50% at 5 yrs, decreasing to 13–33% at 10 yrs [5, 7–12]. However, a recent study by Durante et al. showed a distinction between patients with ¹³¹I uptake with persistent imaging abnormalities, who had an overall survival at 10 yrs of 29%, and those who had a negative ¹³¹I uptake where survival reached 92% [13]. The 10-year survival was as low as 10% in patients in whom metastases showed no initial ¹³¹I uptake. The importance of early diagnosis of functioning DM is thus clearly highlighted. However, the true prognosis for an individual patient with stage IV thyroid cancer is still difficult to assess due to differences in reported outcomes. This is due the heterogeneous analysis of results with regard to timing of development of metastasis, site and extent of disease, age of the patients, histology of the tumour and treatment of the metastatic disease.

Distant metastases are synchronous with the primary diagnosis in 5 to 45 % of patients [6, 11, 12] but could be encountered 5 or 10 years after the initial treatment, thus justifying the prolonged follow-up of thyroid cancer patients [9, 10, 14, 15].

The most common site of metastasis is the lung followed by the bones. Other metastatic areas are less common and involve the mediastinum, brain, liver, skin and so forth. Multi-site disease is associated with a higher rate of mortality that can reach 92% at 5 yrs [7, 12, 16, 17].

Patients with lung metastases have a better outcome compared to other groups [11, 18] whereas bone metastases are usually associated with a poor prognosis [7, 12, 13, 18–26, 28, 29], which might partly be due to the fact that they are rarely detected at an early stage. Among 109 patients with bone metastases described by Bernier et al., only four (4%) had both positive radioiodine uptake and negative standard X-ray examination [19]. Simi-

Correspondence to: Dr. Adil AL-Nahas
Department of Nuclear Medicine, Hammersmith Hospital
Du Cane Road, London W12 0HS
Tel: (+44) 208 383 4923, fax: (+44) 208 383 1700
Email: aal-nahas@hhnt.org

larly, in the study by Durante et al. [13], radiographs were negative at presentation in only eight (7%) of 115 patients. In our recent series of 16 bone metastases among 921 consecutive thyroid cancer patients [30], we found eight patients (50%) in whom bone metastases were first revealed by ^{131}I scanning, and in whom complementary radiological studies were negative. Six of these patients had a very good response to ^{131}I therapy with ^{131}I uptake and thyroglobulin (Tg) levels becoming undetectable or showing a sharp fall. One patient refused ^{131}I therapy and bone metastases became visible on MRI within one year and the Tg level rose 10-fold.

When it is thought that a patient is at high risk of multiple bone metastases, it may be important to make this diagnosis by conventional imaging before withdrawal of thyroid hormone to avoid dramatic potential complications such as neurological compression at the site of spine metastases that may occur at the time of ^{131}I therapy. These patients may require surgery or cementoplasty before hormone withdrawal and ^{131}I therapy. As patients with DM are usually 10 to 15 years older than non-DM controls [9], the presence of DM should be thus suspected in the case of increasing age, as well as in patients with already known DM where multiple organ involvement is possible, but also increasing primary tumour size, extrathyroidal extension, aggressive histology (poorly differentiated follicular tumours, Hürthle cell tumours [31, 32] and insular tumours [33]). Lastly, male gender [9, 33] and multifocality of the primary tumour [34, 35] have also been described as predisposing factors.

The treatment of DTC with metastasis requires total/near-total thyroidectomy followed by radioiodine therapy, which is the treatment of choice in iodine-avid metastases, and which responds favourably to ^{131}I therapy. This is supported by the literature [3, 13, 26, 36, 37]. However, as already mentioned, bone metastases may require additional therapy such as surgery, radiotherapy and/or alternative treatments by arterial embolisation [38] and cementoplasty in emergencies (vertebral compression, fracture, brain metastasis) or as a first line therapy to reduce the tumour burden or as preparation for ^{131}I therapy. Lastly, treatment with bisphosphonates may delay tumour progression and palliate symptoms.

However, high cumulative activities of radioiodine (> 22 GBq; 600 mCi) are associated with a significantly increased risk of leukaemia (which may differ according to whether ^{131}I is used alone or in combination with external beam radiation therapy) [39] and secondary cancers [39, 40]. For this reason, ^{131}I should be repeated only when benefits are expected. Another potential risk from ^{131}I is pulmonary fibrosis in patients with diffuse pulmonary metastases who receive repeated activities of radioiodine over short intervals of time; pulmonary function should therefore be periodically assessed during ^{131}I therapy, especially in young patients [41]. Therefore, the decision to continue or stop ^{131}I therapy at 22 GBq should depend on the risk associated with metastatic disease and should be taken on an individual basis [14, 15].

^{131}I treatment appears highly effective in younger patients with ^{131}I uptake and with small metastases. In the study of Durante et al [13], the best responses (92% 10-yr survival rate) were observed in patients younger than 40 years old with papillary or follicular well-differentiated subtypes and a limited extent of disease; such patients should be treated until the disappearance of any uptake

or until a cumulative activity of 22 GBq is attained. However, in patients who continue to have uptake, the beneficial effects of ^{131}I are difficult to quantify but probably contribute to the reduced 10-yr survival rate that can reach 30% [3, 12, 13, 30, 36]. This is indeed significantly better than the 10-yr survival rate of 10% observed in patients without any detectable uptake, and may be related to different tumour biology and to the beneficial effects of radioiodine therapy [13].

In patients with stable disease over several years with a good quality of life, we recommend that ^{131}I therapy be withheld after 22 GBq and that such patients be monitored with spiral CT scans or MRI and Tg assays, and that further ^{131}I therapy only be given in the event of disease progression [36].

Whenever possible, FDG-PET should be obtained both in patients with non-functioning metastases or those with functioning macrometastases. We believe FDG-PET is an important complementary imaging study in these patients because of its confirmed prognostic impact [42]. It might also help to select candidates for new therapeutic trials in cases of high FDG uptake [43].

Patients with large metastases, poorly differentiated carcinomas and with low or no ^{131}I uptake may be candidates for therapeutic trials with new agents, since the current therapeutic options for such patients are limited [43]. Cytotoxic chemotherapy (especially doxorubicin) has proven to be ineffective in these patients. Redifferentiation therapy by 13-cis retinoic acid (RA) which can induce ^{131}I uptake in about 40% of such patients [44–48] gave great hope in the end of the nineties in patients with loss of differentiation [49], including the loss of radioiodine uptake, but unfortunately the results were controversial [50, 51]. All-trans-retinoic acid (ATRA) has recently been studied [52] and might deserve further investigation. A recent study has demonstrated that histone modification patterns may explain RA-refractoriness in DTC patients and may suggest a potential benefit of combined transcriptional and differentiation therapies [53].

The development of tyrosine kinase inhibitors has recently changed therapeutic strategies in oncology [54], and their role in thyroid cancer management has been underlined in two recent reviews [43, 55]. This new strategy may represent a new hope for such patients, particularly those of older age groups with poorly differentiated tumours who have no or low radioiodine uptake, large metastases, location in bones, rapidly progressive disease and high uptake of FDG. It may also help patients with initial uptake but poor or no response to radioiodine treatment and those with no initial uptake of radioiodine, especially when the disease is progressive. The results of molecular targeted therapies and anti-angiogenic agents, which are being studied in prospective controlled trials, are therefore anticipated with great interest.

References

- Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998; 338: 297–306.
- Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. *Laryngoscope* 2005; 115: 661–667.
- Casara D, Rubello D, Saladini G et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. *J Nucl Med* 1993; 34: 1626–1631.

4. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. *Am J Surg* 1997; 174: 474–476.
5. Hoie J, Stenwig AE, Kullmann HR, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. *Cancer* 1988; 61: 1–6.
6. Benbassat CA, Mechlis-Frsh S, Hirsch D. Clinico-pathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid carcinoma. *World J Surg* 2006; 30: 1088–1095.
7. Ruegemer JJ, Hay ID, Bergstrahl EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma. A multivariate analysis of prognosis variables. *J Clin Endocrinol Metab* 1988; 67: 501–508.
8. Dinneen SF, Valimaki MJ, Bergstrahl EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. *J Clin Endocrinol Metab* 1995; 80: 2041–2045.
9. Lin JD, Huang MJ, Juang JH et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. *Thyroid* 1999; 9: 1227–1235.
10. Beasley NJ, Walfish PG, Witterick I, Freeman JL. Cause of death in patients with well-differentiated thyroid carcinoma. *Laryngoscope* 2001; 111: 989–991.
11. Shoup M, Stojadinovic A, Nissan A et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. *J Am Coll Surg* 2003; 197: 191–197.
12. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. *Clin Endocrinol (Oxf)* 2005; 63: 87–93.
13. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab* 2006; 91: 2892–2899.
14. Cooper DS, Doherty GM, Haugen BR et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006; 16: 109–142.
15. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 2006; 154: 787–803.
16. Schlumberger M, Tubiana M, De Vathaire F et al. Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 1986; 63: 960–967.
17. Lin JD, Chao TC, Hsueh C. Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study. *Endocr J* 2004; 51: 219–225.
18. Schlumberger M, Challeton C, de Vathaire F et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. *J Nucl Med* 1996; 37: 598–605.
19. Bernier MO, Leenhardt L, Hoang C et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. *J Clin Endocrinol Metab* 2001; 86: 1568–1573.
20. Brown AP, Greening WP, McCreedy VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. *Br J Radiol* 1984; 5: 323–327.
21. Eustatia-Rutten CF, Romijn JA, Guijt MJ et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2003; 88: 3184–3189.
22. Marcocci C, Pacini F, Elisei R et al. Clinical and biological behavior of bone metastases from differentiated thyroid carcinoma. *Surgery* 1989; 106: 960–966.
23. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. *Surgery* 1986; 100: 1088–1097.
24. Pacini F, Cetani F, Miccoli P et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. *World J Surg* 1994; 18: 600–604.
25. Petrich T, Widjaja A, Musholt TJ et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. *Eur J Nucl Med* 2001; 28: 203–208.
26. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. *Thyroid* 2000; 10: 261–268.
27. Proye CA, Dromer DH, Carnaille BM et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? *World J Surg* 1992; 16: 640–646.
28. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP, Links TP. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2000; 52: 653–659.
29. Zettinig G, Fueger BJ, Passler C et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma — surgery or conventional therapy? *Clin Endocrinol (Oxf)* 2002; 56: 377–382.
30. Hindié E, Zanotti-Fregonara P, Keller I et al. Bone metastases of differentiated thyroid cancer: impact of early ¹³¹I-based detection on outcome. *Endocr Relat Cancer (in pres)*.
31. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. *Thyroid* 2001; 11: 637–645.
32. Albareda M, Puig-Domingo M, Wengrowicz S et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. *Thyroid* 1998; 8: 385–391.
33. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. *Eur J Cancer* 1992; 29A: 44–51.
34. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. *Am J Med* 1981; 70: 511–518.
35. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. *Cancer* 1985; 55: 805–828.
36. Hindié E, Melliere D, Lange F et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? *Eur J Nucl Med Mol Imaging* 2003; 30: 974–981.
37. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastases of differentiated thyroid carcinoma: treatment results in 101 patients. *J Clin Endocrinol Metab* 1985; 60: 376–380.
38. Smit JWA, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carcinoma. *J Clin Endocrinol Metab* 2000; 85: 989–994.
39. de Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. *Br J Cancer* 1997; 75: 734–739.
40. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. *Br J Cancer* 2003; 89: 1638–1644.
41. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. *J Nucl Med* 1998; 39: 1531–1536.
42. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[¹⁸F] fluoro-2-deoxy-d-glucose positron emission tomography. *J Clin Endocrinol Metab* 2006; 91: 498–505.

43. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. *Lancet Oncol* 2007; 8: 148–156.
44. Simon D, Koehle J, Reiners C et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. *World J Surg* 1998; 22: 569–574.
45. Grunwald F, Menzel C, Bender H et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. *J Nucl Med* 1998; 39: 1903–1906.
46. Koerber C, Schmutzler C, Rendl J et al. Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. *Clin Nucl Med* 1999; 24: 849–851.
47. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. *Thyroid* 2000; 10: 393–406.
48. Toubert ME, Darsin D, Cassinat B et al. Redifferentiation therapy with retinoids for radioiodine negative thyroid cancer patients. *Eur J Nucl Med Mol Imaging* 2003; 30 (O106): S172.
49. Filetti S, Bidart JM and Arturi F. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. *Eur J Endocrinol* 1999; 141: 443–457.
50. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer — does it hold its promise? *Eur J Endocrinol* 2003; 148: 395–402.
51. Courbon F, Zerdoud S, Bastie D et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. *Thyroid* 2006; 16: 1025–1031.
52. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. *Nucl Med Commun* 2007; 28: 251–255.
53. Cras A, Darsin-Bettinger D, Balitrand N et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. *Oncogene* 2007; 26: 4018–4024.
54. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med* 2005; 353: 172–187.
55. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. *Nat Clin Pract Endocrinol Metab* 2006; 2: 42–52.